A study of Rambazole, a novel retinoic acid metabolism blocking agent (Ramba) revealed that 94 percent of subjects with moderate to severe acne treated with 1 mg orally once daily for 12 consecutive weeks Rambazole experienced reduced acne lesions total number of over 50 percent and 35 percent were considered “cleared or almost cleared.

This study shows that production of this drug in the future because Barrier Therapeutics, Inc. Positive Phase 2a data for its oral formulation of Rambazole (TM) in the treatment of moderate to severe acne and reported positive data from biological activity for its courses formulation of this product.

Experts expose a subject that should have cut more than 90 per cent in total lesions to be considered “authorized or almost obliterated.” According to their report, the inflammatory and non inflammatory response as well to treatment. It n ‘there was no serious consequences on treatment with this new feature. Only a small number of patients in the study group experienced dry skin and lips as non-serious adverse events.

Geert Cauwenbergh, Ph.D., president and CEO of Barrier Therapeutics, Inc., explained that “these positive Phase 2a results indicate that oral Rambazole is active in moderate to severe inflammatory acne, and, according to the results of future large-scale clinical trials, the drug could one day meet the need of safe and effective orally for moderate to severe acne. These results are based on our previously announced promising clinical data for oral Rambazole for psoriasis.